Floatz logo

Romidepsin

Childhood Acute Lymphoblastic Leukemia in Remission

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Childhood Acute Lymphoblastic Leukemia in Remission cohort.

Asset / SponsorPhaseRating
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
Monomethyl Fumarate
Stanford University
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB

View all 24 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →